Know Cancer

forgot password

A Phase III Randomized, Double Blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Phase 3
18 Years
Open (Enrolling)
Breast Cancer

Thank you

Trial Information

A Phase III Randomized, Double Blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Research summary (NRES, UK):

Breast cancer is the most commonly diagnosed cancer in women and the leading cause of
cancer-related death among women worldwide.

However, despite advances in treatment of the early-stage disease, about 25-40% of patients
will develop recurrence or spread to other parts of the body that is largely incurable. The
average survival of patients with breast cancer that has spread to other parts of the body
(metastasis) is 2 to 3 years after diagnosis, and although a number of treatment options are
available, including various chemotherapy agents, no single standard of care exists.

The study drug (Sorafenib) works by inhibiting certain pathways in the body that contribute
to tumour growth and the formation of new blood vessels (angiogenesis). Angiogenesis plays
an important role in the development, transformation and spread of breast cancer.
Capecitabine is an approved chemotherapy drug for patients whose breast cancer has spread to
other parts of the body (metastatic) and is not responsive to other classes of chemotherapy

Data from a Phase IIb clinical study suggests that there is a role for the combination of
Sorafenib and Capecitabine to treat locally advanced or metastatic breast cancer.

Patients in this confirmatory Phase III study will be randomly assigned to receive either:

- Capecitabine + Sorafenib

- Capecitabine + placebo ("dummy medication" with no active drug)

Participants will continue to receive treatments until there is radiographic or clinical
progression of disease, side effects which require them to withdraw, pregnancy, protocol
non-compliance or withdrawal of consent. Therefore length of participation will vary for
individuals. This study is expected to close 31 March 2013.

This is a multicentre study which will take place across Europe, North and South America,
Asia, Australia and South Africa. It is anticipated that approximately 519 participants will
be recruited worldwide.

Inclusion Criteria:

- Age is >=18 years

- Subject has histologically or cytologically confirmed HER2-negative adenocarcinoma of
the breast. HER2 status should be determined by an accredited laboratory

- Subject has locally advanced or metastatic disease; locally advanced disease must not
be amenable to resection with curative intent. Must have measurable or non-measurable
disease (according to RECIST 1.1)

- All computer tomography (CT; with contrast) and magnetic resonance imaging (MRI) used
to document disease must have been done <= 4 weeks before randomization. Bone scans
(if clinically indicated) must have been done <= 12 weeks prior to randomization

- Subject must have received up to two prior chemotherapy regimens
(adjuvant/neo-adjuvant treatments are considered one regimen), and no more than one
prior regimen for advanced and/or metastatic disease. Chemotherapy regimens include
both targeted and biologic therapy

- Prior regimens must have included an anthracycline (eg, doxorubicin, epirubicin) and
a taxane (eg, paclitaxel, docetaxel), either in combination or in separate regimens,
in either the neo-adjuvant/adjuvant or the metastatic setting or both, as either
monotherapy or as part of a combination with another agent. Sequential regimens will
count as a single regimen; multiple neo-adjuvant / adjuvant regimens will count as a
single regimen

- Subjects are either resistant to or have failed prior taxane and anthracycline OR
Resistant to or have failed prior taxane AND for whom further anthracycline therapy
is not indicated (for example, intolerance or cumulative doses of doxorubicin or
doxorubicin equivalents [for example, epirubicin)

- Subjects who relapse beyond 12 months after the last taxane or anthracycline dose
given in the adjuvant, neo-adjuvant, or metastatic setting are eligible. Further
therapy with the agent(s) for a subsequent regimen must have been considered and
ruled out, for example due to prior toxicity or intolerance, or based on the local
standard of practice

- Prior experimental chemotherapy treatment is allowed, provided it is given in
combination with at least one drug approved for the treatment of breast cancer
(excluding drugs that target VEGF or VEGFR, eg, bevacizumab, brivanib, sunitinib,

- Prior hormonal therapy for locally advanced or metastatic breast cancer is allowed.
Subjects who are refractory to hormonal therapy are allowed.

- Prior neo-adjuvant or adjuvant chemotherapy is allowed.

- Subject must have discontinued prior chemotherapy (including both targeted and
biologic therapies), prior therapeutic radiation therapy, or prior hormonal therapy
for locally advanced or metastatic disease >= 4 weeks (28 days) before randomization.
Start of study treatment is allowed within less than 28 days of the prior therapy
provided that 5 half-lives of the prior treatment drug(s) have elapsed

- ECOG performance status 0 or 1

- Adequate bone marrow, liver and renal function within 7 days prior to randomization

- All acute toxic effects of any prior treatment have resolved to NCI-CTCAE v4.0 Grade
1 or less

- Women of childbearing potential must have a negative serum pregnancy test performed
within 7 days prior to randomization

- Subjects (men and women) of childbearing potential must agree to use adequate
contraception beginning at the signing of the ICF until at least 30 days after the
last dose of study drug.

- Subject must be able to swallow and retain oral medication

Exclusion Criteria:

- HER2 positive breast cancer

- Unknown hormone receptor status (estrogen and progesterone receptor).

- Subjects with bilateral breast cancer or a history of two distinct breast cancers.

- Subjects with inflammatory breast carcinoma.

- Subjects who have received no prior taxane and anthracycline for the treatment of
breast cancer (either in adjuvant, neo-adjuvant or metastatic setting).

- Prior use of sorafenib or capecitabine

- Subjects considered by the treating investigator to be appropriate candidates for
hormonal therapy as current treatment for locally advanced/metastatic breast cancer

- Subjects with locally advanced disease who are considered by the treating
investigator to be appropriate candidates for radiation therapy as current treatment
for locally advanced breast cancer

- Subjects with active brain metastases or leptomeningeal disease.

- Subjects with seizure disorder requiring medication.

- Radiation to any lesions <= 4 weeks prior to randomization. Palliative radiation to
bone metastasis for pain control is permitted with provisions

- Major surgery, open biopsy, or significant traumatic injury <= 4 weeks

- Evidence or history of bleeding diathesis or coagulopathy. Uncontrolled hypertension,
active or clinically significant cardiac disease. Subject with thrombotic, embolic,
venus or arterial events

- Subjects with any hemorrhage/bleeding event of NCI-CTCAE v4.0 Grade 3 or higher
within 4 weeks before randomization

- Subjects with an infection of NCI-CTCAE v4.0 > Grade 2

- Subjects with a history of human immunodeficiency virus infection or current chronic
or active hepatitis B or C infection.

- Subjects who have used strong CYP3A4 inducers (eg, phenytoin, carbamazepine,
phenobarbital, St. John's Wort [Hypericum perforatum], dexamethasone at a dose of
greater than 16 mg daily, or rifampin [rifampicin], and/or rifabutin) within 28 days
before randomization.

- Subjects with any previously untreated or concurrent cancer that is distinct in
primary site or histology from breast cancer

- Subjects with a history DHPD reaction to fluropyrimidine or history of known or
suspected allergy or hypersensitivity to any of the study drugs

- Presence of a non-healing wound, non-healing ulcer, or bone fracture

- Women pregnant or breast feeding

- Any condition which, in the investigator's opinion, makes the subject unsuitable for
trial participation

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Progression-free survival (PFS): radiological assessment according to RECIST 1.1 criteria for progression

Outcome Time Frame:

Date of randomization of first patient to 48 months later

Safety Issue:


Principal Investigator

Bayer Study Director

Investigator Role:

Study Director

Investigator Affiliation:



Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica

Study ID:




Start Date:

February 2011

Completion Date:

April 2014

Related Keywords:

  • Breast Cancer
  • Breast Cancer
  • HER2-neu
  • Breast Neoplasms



Hinsdale, Illinois  60521
Albany, Georgia  31701
Fountain Valley, California  92708
Miami, Florida  33176
Columbia, Missouri  65203
Albany, New York  12208
Philadelphia, Pennsylvania  19104
Nashville, Tennessee  37203-1632
Austin, Texas  78705
Seattle, Washington  98195
Louisville, Kentucky  40207
McLean, Virginia  22101
Albuquerque, New Mexico  87131-5636
Metairie, Louisiana  70006
Boston, Massachusetts  
Charlotte, North Carolina  
South Burlington, Vermont  
Milwaukee, Wisconsin  
Indianapolis, Indiana  
Jackson, Mississippi